Table 2 Biochemical pathways altered by Saroglitazar treatment in disease model
Reactome pathways | No. of entities found | Total no. of entities | Fold enrichment | P-value | Regulation |
|---|---|---|---|---|---|
Triglyceride catabolism | 5 | 20 | 19.45 | 3.1 X 10−2 | Up |
Beta-oxidation of fatty acids | 10 | 39 | 16.05 | 4.1 X 10−5 | Up |
Alpha-linolenic acid (ALA) metabolism | 9 | 46 | 13.41 | 6.1 X 10−4 | Up |
Mitochondrial Fatty Acid Beta-Oxidation | 26 | 110 | 11.23 | 1.4 X 10−10 | Up |
Peroxisomal lipid metabolism) | 20 | 96 | 10.1 | 1.5 X 10−6 | Up |
Triglyceride metabolism | 10 | 49 | 8.69 | 2.9 X 10−3 | Up |
Peroxisomal protein import | 24 | 80 | 7.36 | 3.5 X 10−9 | Up |
Bile acid and bile salt metabolism | 9 | 139 | 7.32 | 4.8 X 10−2 | Up |
Fatty acyl-CoA biosynthesis | 11 | 76 | 7.15 | 1.5 X 10−3 | Up |
Fatty acid metabolism | 83 | 458 | 7.02 | 5.7 X 10− 28 | Up |
Glycerophospholipid biosynthesis | 25 | 247 | 4.83 | 2.6 X 10−7 | Up |
Metabolism of lipids | 150 | 1383 | 4.47 | 3.1 X 10−41 | Up |
Biological oxidations | 60 | 662 | 4.12 | 2.2 X 10−12 | Up |
Metabolism of steroids | 20 | 299 | 3.69 | 7.8 X 10−4 | Up |
Phospholipid metabolism | 27 | 378 | 3.28 | 1.6 X 10−4 | Up |
Metabolism | 274 | 3564 | 2.96 | 1.1 X 10− 49 | Up |
Degradation of the extracellular matrix | 10 | 169 | 5.85 | 2.3 X 10−2 | Down |
Extracellular matrix organization | 52 | 393 | 2.63 | 3.2 X 10−3 | Down |